Quia Pharma AB (publ)

As of December 31, 2022, Quia Pharma AB (publ) has 6.39M shares outstanding.

These figures are as of December 31, 2022.

As of December 31, 2022, Quia Pharma AB (publ) maintains a current ratio of 0.65, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 643.53, indicating elevated leverage, while an interest coverage ratio of -4.25 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2022. Return on assets (ROA) is negative at -85.11, reflecting losses generated across the asset base.

These figures cover the twelve months ended December 31, 2022. Free cash flow yield is negative at -22.87: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -38.06, meaning Quia Pharma AB (publ) raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Quia Pharma AB (publ)'s most recent stock split took place on August 1, 2023 with a 100:1 split ratio.

As of December 31, 2022, Quia Pharma AB (publ) has an Altman Z-Score of -31.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.